Magnesium in CKD: more than a calcification inhibitor?

Jürgen Floege

Abstract Magnesium fulfils important roles in multiple physiological processes. Accordingly, a tight regulation of magnesium homeostasis is essential. Dysregulated magnesium serum levels, in particular hypomagnesaemia, are common in patients with chronic kidney disease (CKD) and have been associated with poor clinical outcomes. In cell culture studies as well as in clinical situations magnesium levels were associated with vascular calcification, cardiovascular disease and altered bone-mineral metabolism. Magnesium has also been linked to diseases such as metabolic syndrome, diabetes, hypertension, fatigue and depression, all of which are common in CKD. The present review summarizes and discusses the latest clinical data on the impact of magnesium and possible effects of higher levels on the health status of patients with CKD, including an outlook on the use of magnesium-based phosphate-binding agents in this context.

Keywords Magnesium · Chronic kidney disease · Cardiovascular disease · Diabetes · Depression

Introduction

As the fourth most abundant cation in the body, magnesium fulfils an important role in multiple physiological processes. Over 300 enzymes require the presence of magnesium for their catalytic action, including many enzymes utilising or synthesising ATP, or those that use other nucleotides to synthesise DNA and RNA. While clinical issues regarding magnesium disorders had received surprisingly little attention until the 1990s, a shift in focus led to some clinical investigations, especially in patients with chronic kidney disease (CKD). In 2012, several reviews on magnesium metabolism and disorders in magnesium balance were published in a special issue of the Clinical Kidney Journal [1]. Given the growing interest in the molecule since then the literature on the role of magnesium in CKD has continued to accumulate substantially. For instance, two cohort studies established hypomagnesaemia as a predictor of mortality (Fig. 1) and kidney function decline in CKD patients [2] as well as mortality in haemodialysis (HD) patients [3]. Furthermore, magnesium was identified as an independent risk factor for non-recovery of renal function in a cohort of critically ill patients with acute kidney injury [4].

This review examines and reviews the clinical impact of magnesium on the health status of CKD patients, in particular taking into account the influence of magnesium on diseases such as metabolic syndrome, diabetes, hypertension, vascular calcification and cardiovascular events, fatigue and depression all of which are frequently present in CKD patients and/or contribute to CKD progress.

Magnesium and vascular calcification

Cardiovascular disease (CVD) is the leading cause of death in the CKD population [5]. The high prevalence of vascular calcification contributes significantly to this cardiovascular risk [6]. The molecular mechanisms leading to vascular calcification in CKD patients are still under investigation, but there is consensus that it is an active, multifactorial, cell-mediated and dynamic process [7, 8]. The progressive loss of kidney function is accompanied by elevated serum
fibroblast growth factor 23 (FGF23) levels, a decrease in inorganic phosphate excretion and dysregulation of mineral and bone metabolism. These disturbances promote vascular calcification, whereby vascular smooth muscle cells (VSMCs) play a central role in the pathogenesis by undergoing an osteochondrogenic phenotype change in response to elevated phosphate levels [9].

Several cell culture and animal studies suggest a protective role of magnesium through multiple molecular mechanisms [10–12]. These results were extended by recent studies in which magnesium was shown to inhibit phosphate-induced calcification in vitro [13]. Moreover, higher magnesium levels prevented calcification of bovine VSMCs, inhibited expression of osteogenic proteins, apoptosis and further progression of already established calcification [14]. The first in vitro evidence in human aortic VSMCs for a protective role of magnesium on phosphate-induced calcification was based on the observation that living cells are necessary for magnesium ions to exert its protective effect. These studies suggested a potentially active intracellular role of magnesium on phosphate-induced calcification was based on the observation that living cells are necessary for magnesium ions to exert its protective effect. These studies suggested a potentially active intracellular role of magnesium ions in attenuating the vascular calcification process [15]. Additionally, increasing magnesium concentrations improved cell viability and normalised the cellular release of proteins involved in vascular calcification [15]. Inhibition of the Wnt/β-catenin signalling pathway was identified as one of the intracellular mechanisms by which the anti-calcifying effect of magnesium is achieved [16]. In the context of these data, microcalcifications in human atherosclerotic lesions contain both calcium and magnesium (in the form of whitlockite and calcium phosphate/apatite); whereas CKD- accelerated calcification was associated with a predominant deposition of calcium phosphate/apatite [17].

This suggests that in CKD, local magnesium homoeostasis is disturbed and potentially aggravates vascular calcifications.

The clinical relation between serum magnesium and vascular changes including calcification was assessed in several recent studies. A prospective study in 47 HD patients revealed an association of magnesium serum concentration with the intima–media thickness of carotid arteries [13]. In addition, CKD patients with higher magnesium serum concentrations had a significantly lower pulse wave velocity (PWV). Similarly, a cohort study of 512 renal transplant recipients identified low magnesium levels as a predictor of PWV and thus of vascular stiffness, independent of clinically relevant covariates and especially in older patients [18]. Furthermore, an observational cohort study, investigating 283 CKD patients, reported an association of high magnesium levels with less endothelial dysfunction [19].

So far, one double-blind, placebo-controlled randomised trial examined the efficacy of oral magnesium oxide (440 mg three times per week for 6 months) on endothelial function in HD patients [20]. While magnesium supplementation significantly decreased carotid intima–media thickness, there were no significant effects on C-reactive protein or flow-mediated dilatation, i.e. a functional endothelial marker [20]. The study was limited by the small sample size (less than 30 patients per treatment arm) and a significant baseline imbalance in intima–media thickness between the groups. Another small study in 47 dialysis patients randomised to no therapy or 610 mg magnesium citrate orally every other day for 2 months also noted a reduction of carotid intima–media thickness accompanied by a reduction in PTH levels [21]. Thus, more prospective interventional studies are warranted to assess the potential benefits of magnesium supplementation on vascular dysfunction and calcification.

**Magnesium and CVD**

A meta-analysis of 19 prospective studies including 532,979 participants found a significant inverse association between magnesium intake and/or serum levels and the risk of CVD events in different patient populations [22]. This relationship was further sustained by a comprehensive study in 7,216 Spanish high-risk patients for cardiovascular disease. Again, an inverse association was noted between dietary magnesium intake and all-cause mortality [23].

While the above studies did not focus on CKD patients, several smaller studies did. In 80 diabetic CKD stage 2–4 patients, low serum magnesium was identified as a significant risk factor for an elevated pulse pressure, an established marker for cardiovascular mortality [24]. Analyses
in 191 diabetics with CKD stage 1–3 have further underlined the relevance of this finding as lower magnesium levels are associated with increased mortality and accelerated progression of renal disease [25]. A third observational cohort study in 283 CKD patients also identified magnesium as an independent predictor of future cardiovascular outcomes [19]. In this study, Kaplan–Meier curves showed significantly higher cardiovascular mortality rates in CKD patients whose serum magnesium levels were below 2.05 mg/dL (0.84 mmol/L). Finally, these results were confirmed in a recent registry-based cohort study of 142,555 HD patients that again identified low serum magnesium as a significant predictor of cardiovascular mortality [3].

Thus, observational studies consistently identify low serum magnesium levels as a predictor or risk factor of vascular pathology, cardiovascular morbidity and all-cause mortality. However, recent large-scale randomised clinical trials [the Fourth International Study of Infarct Survival (ISIS 4) and Magnesium in Coronaries (MAGIC)] in non-renal patients could not prove a benefit of intravenous magnesium after myocardial infarction, and magnesium therapy is presently only indicated in patients with life-threatening ventricular arrhythmias [26]. Whether the situation is different in CKD patients with ischaemic heart disease remains to be tested.

**Magnesium and bone-mineral metabolism**

The association between magnesium and mineral metabolism was recently investigated in several animal studies. To elucidate the effect of magnesium on phosphate homeostasis, rats were fed either a normal or magnesium-deficient diet. Magnesium deficiency induced high serum FGF23 levels, possibly contributing to the observed decrease in renal phosphorus reabsorption [27]. While direct effects of magnesium on FGF-23 are not well established, the administration of a calcium acetate/magnesium carbonate (CaMg) containing phosphate binder in dialysis patients lowered both serum phosphate and FGF-23 [28]; in another study magnesium oxide also lowered FGF-23 levels in dialysis patients [29]; high magnesium concentrations can also activate the calcium-sensing receptor and thereby modulate PTH secretion in similar manner to calcium, albeit less potently [30, 31]. Another study demonstrated increasing serum 1,25-dihydroxyvitamin D and decreasing PTH as well as phosphate levels in response to magnesium loading in mouse models with genetic inactivation of PTH or both, PTH and the calcium-sensing receptor [32]. Both studies indicate the importance of balanced magnesium intake in terms of regulated phosphorus levels.

Since clinical studies have demonstrated the efficacy of magnesium-containing phosphate binders [33], and in line with the study by Quinn and colleagues [32], some concern has arisen that high serum magnesium or magnesium loading might oversuppress PTH secretion. In this context, an in vitro study with intact rat parathyroid glands is of importance, which showed that parathyroid glands were sensitive to an inhibitory effect of magnesium only when a moderately low calcium concentration was present [34]. The general dialysis population, however, does not have low calcium concentrations; and this issue warrants more clinical studies.

In addition to influencing PTH secretion, magnesium affects the synthesis and metabolism of vitamin D [32]. Many epidemiologic studies suggest that low vitamin D status may be associated with an increased risk of all-cause mortality [35–37]. Importantly, the activities of three major enzymes determining 25-hydroxyvitamin D3 (25(OH)D3) level [38–41] and vitamin D-binding protein [39] are magnesium dependent. Indeed, a cohort study including 12157 NHANES III participants indicated that the inverse associations between serum 25(OH)D3 and risk of mortality could be modified by the intake level of magnesium [42].

Although once again randomised controlled studies are missing, the importance of magnesium for the mineral metabolism seems likely.

Effects of magnesium on bone in uremic patients have been reviewed recently [43]. In summary, various authors have hypothesized that magnesium might contribute to osteomalacia and/or renal osteodystrophy in particular via suppressing PTH [43]. However, in vivo confirmation of this in dialysis patients is lacking and there is at present no conclusive evidence that magnesium administration in CKD is associated with adynamic bone disease. Of note, in the CALMAG trial, administration of a CaMg-containing phosphate binder to dialysis patients did not affect markers of bone turnover over 6 months [28]. Epidemiological studies in non-CKD populations have linked magnesium deficiency to low bone mass and osteoporosis [44].

**Magnesium and hypertension**

Previous studies on the risk of hypertension and ischaemic heart disease have shown only a modest effect [45–48], or inconsistent results [49–54], regarding its correlation to dietary magnesium intake (and serum magnesium levels). This was mainly due to a lack of direct measures of actual magnesium uptake. Serum levels of magnesium only correlate weakly with its intake unless extreme conditions prevail (e.g. excessive oral administration of magnesium salts) [55]. Thus, the use of urinary
magnesium excretion as a more precise indicator of dietary magnesium uptake might provide a better insight into this association. In fact, results from a recent prospective population-based cohort study with 5,511 participants free of hypertension at baseline, demonstrated that urinary magnesium excretion was inversely associated with the risk of developing hypertension [56]. The same study group investigated the association between magnesium uptake and ischaemic heart disease in 7,664 participants free from known CVD at baseline. Again, low urinary magnesium excretion was independently associated with a higher incidence risk [57]. The authors suggest that an increased dietary magnesium intake, in particular in those persons with a low urinary excretion of magnesium, could reduce the risk of ischaemic heart disease, lower blood pressure and prevent hypertension [56, 57]. A recently published cross-sectional study, involving 175 healthy subjects, supports the proposed pathophysiological role of magnesium in the development of hypertension: here a lower magnesium concentration was the only significant parameter in a multivariate analysis between pre-hypertensive and normotensive subjects [58]. However, so far clinical trials have not detected significant antihypertensive effects of magnesium supplementation alone [59] but rather suggest that magnesium might augment the response to antihypertensive drugs [60].

Magnesium and diabetes mellitus

Diabetes is the most frequent primary cause of CKD [61]. Hypomagnesaemia occurs with an incidence of 14–48 % among patients with T2DM compared with 3–15 % among their counterparts without diabetes [62]. A recent meta-analysis of thirteen prospective cohort studies involving 536,318 participants and 24,516 cases of diabetes provided further evidence that magnesium intake is inversely associated with the risk of T2DM [relative risk (RR) 0.78 (95 % CI 0.73–0.84)] in a dose–response manner (Fig. 2) [63]. Magnesium deficiency has also been linked to the development of the disease as well as its severity: the lower the magnesium level, the faster the deterioration of renal function in patients with type 2 diabetes mellitus (T2DM) [64].

Correction of hypomagnesaemia via dietary magnesium supplementation improved glucose handling and insulin response in elderly and non-insulin-dependent diabetics [65] and improved insulin sensitivity as well as metabolic control in T2DM patients with decreased serum magnesium levels [66]. The relationship between magnesium intake and metabolic parameters was further investigated in a cross-sectional study involving 210 elderly T2DM patients, of which 89 % exhibited a low magnesium intake and 37 % had overt hypomagnesaemia [67]. Metabolic syndrome and depression were associated with low intake,
but not metabolic parameters, such as HbA1c, low high-density cholesterol, triglycerides and blood pressure. In support of the well-known association between lower serum magnesium levels and impaired renal function, results from a cross-sectional study involving 51 T2DM patients showed that CKD was accompanied by hypomagnesaemia including low intracellular magnesium content of red cells most likely as a result of low intake [68]. In this study, magnesium deficiency was associated with poor blood glucose control and thus a potential increased risk of subsequent CVD events.

In line with this, T2DM is known to significantly increase the risk of ventricular arrhythmias, which represent a serious issue in CKD patients [69]. Results from a recent cross-sectional health survey among 750 adults with high T2DM prevalence showed that in diabetics the odds ratio of premature ventricular complexes was 0.24 (95% CI 0.06–0.98) if serum magnesium was above 0.70 mmol/L compared to those where it was ≤0.70 mmol/L [70]. Thus, subnormal serum magnesium may be a contributor to arrhythmias among patients with T2DM, and conceivably magnesium supplementation in adults with T2DM may confer protection against ventricular arrhythmias.

Despite the growing body of evidence on the relation between hypomagnesaemia and insulin resistance in T2DM, the molecular aetiology is poorly understood. Transient receptor potential membrane melastatin (TRPM)-6 is an ion channel which is crucial for magnesium homoeostasis and plays an essential role in epithelial magnesium transport as well as in the active magnesium reabsorption in the gut and kidney. Two rare single nucleotide polymorphisms in TRPM6 (V1393I, K1584E) conferred susceptibility for T2DM but only if magnesium intake was low (<250 mg/day) [71]. Insulin stimulates TRPM6 activity via elevating the cell surface expression of TRPM6 but this mechanism fails with the above genetic variants TRPM6 [72]. Thus, these studies identify a direct molecular link between diabetes and magnesium and thus potentially link magnesium homoeostasis to diabetic outcomes.

Serum magnesium levels negatively correlated with HbA1c, fasting plasma glucose and microalbuminuria [73]. To better elucidate the relationship between magnesium deficiency and advanced T2DM nephropathy, a retrospective cohort study was conducted in 455 CKD patients. Hypomagnesaemia was significantly associated with and independently predicted progression to ESRD in patients with T2DM nephropathy but not in those with non-diabetic CKD [74]. In line with this observation, a later publication linked magnesium concentrations to the rate of kidney function decline [2]. However, in this latter study, the effect of magnesium lost significance after adjustment for additional covariates, in particular diuretics. Thus, whether magnesium supplementation may delay the onset of T2DM or its renal complications remains unknown at present.

### Magnesium and fatigue/depression

Fatigue involves general, mental and physical fatigue reduced motivation and reduced activity dimensions [75]. It is one of the most frequent dialysis-associated symptoms with prevalences reported from 60 and up to 97% [76]. Fatigue is often accompanied by depression, and major depressive disorders are as well very common among CKD and ESRD patients, affecting 20% of CKD patients compared to a prevalence of 2–10% in the general population [77]. The fact that only a minority of affected CKD patients (~20%) receives an adequate diagnosis and treatment for depression, poses a major challenge for clinicians to develop strategies to better understand and manage depression in this population [77].

Basic research reveals the involvement of magnesium ions in pathways which are connected to the known pathophysiology of depression. The N-methyl-D-aspartate (NMDA)-ergic system received marked attention in the context of developing new compounds for mood disorders in recent years [78]. The magnesium ion is a naturally occurring NMDA-receptor antagonist, and reduced intracellular magnesium ions can be responsible for an increased NMDA receptor sensitivity [79]. Besides NMDA targets involved in the antidepressant action of magnesium, there are brain-derived neurotrophic factors (BDNF) and glycogen synthase kinase-3 (GSK-3). Magnesium increases BDNF and both inhibit the activity of GSK-3, an enzyme involved in the mechanisms of action of antidepressants [80]. Magnesium is also a cofactor of tryptophan hydroxylase, which catalyses serotonin synthesis. Hence levels of serotonin and BDNF increase in the presence of magnesium, leading to an improvement of depressive symptoms.

Animal data indicated that short-term administration of magnesium possesses potent antidepressant-like properties in the forced swim test in mice [81]. No development of tolerance was observed after prolonged treatment [82]. An early study in non-renal patients with chronic fatigue indeed noted low intracellular magnesium levels, and magnesium supplementation led to some clinical improvement [83]. Further evidence was gained in one randomised controlled trial comparing the efficacy of oral magnesium supplementation with the standard antidepressant imipramine in a 12-week treatment of newly diagnosed depression in twenty-three elderly with T2DM and hypomagnesaemia. Here, oral magnesium supplementation with MgCl2 (equivalent to 450 mg of elemental magnesium) was as effective as 50 mg imipramine daily, the prototypic medication in depression [84]. However, of
intake compared to pure calcium-based phosphate binders [85]. In an animal study, the ensuing mildly elevated magnesium levels resulted in beneficial effects in terms of calcification, PTH levels and survival [86]. Clinical data further demonstrated that CaMg does not negatively influence bone health and might even help to maintain it, causing neither an overstimulation nor a suppression of bone turnover (Fig. 3) [28]. In view of the above discussion, therapy with CaMg in hyperphosphataemic CKD patients offers the exciting option to also evaluate whether the many pleiotropic actions of magnesium beneficially influence health issues beyond bone mineral disease.

Acknowledgments The author thanks Dr Petra Jöstingmeier for providing writing and editorial assistance.

Conflict of interest The author has received honoraria from Amgen, Abbvie, Fresenius, Sanofi and Shire.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Luft C (2012) Magnesium—a versatile and often overlooked element: new perspectives with a focus on chronic kidney disease. Clin Kidney J 5(Suppl 1). doi:10.1093/ndtplus/sfs035
2. Van Laecke S, Nagler EV, Verbeke F, Van Biesen W, Vanholder R (2013) Hypomagnesaemia and the risk of death and GFR decline in chronic kidney disease. Am J Med 126(9):825–831. doi:10.1016/j.amjmed.2013.02.036
3. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y (2014) Hypomagnesaemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 85(1):174–181. doi:10.1038/ki.2013.327
4. Alves SC, Tomasi CD, Constantino L et al (2013) Hypomagnesaemia as a risk factor for the non-recovery of the renal function in critically ill patients with acute kidney injury. Nephrol Dial Transplant 28(4):910–916. doi:10.1093/ndt/gfs268
5. Foley RN, Parfrey PS (1998) Cardiovascular disease and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 85(1):174–181. doi:10.1038/ki.2013.327
6. Shanahan CM (2006) Vascular calcification—a matter of damage limitation? Nephrol Dial Transplant 21(5):239–245
7. Shanahan CM (2006) Vascular calcification—a matter of damage limitation? Nephrol Dial Transplant 21(5):239–245
8. Shanahan CM (2006) Vascular calcification—a matter of damage limitation? Nephrol Dial Transplant 21(5):239–245
9. Shanahan CM (2006) Vascular calcification—a matter of damage limitation? Nephrol Dial Transplant 21(5):239–245
10. Peters F, Eppele M (2001) Simulating arterial wall calcification in vitro: biomimetic crystallization of calcium phosphates under
controlled conditions. Z Kardiol 90(Suppl3):81–85. doi:10.1007/s0039201700047

11. Altura BM, Altura BT, Carella A, Gebrewold A, Murakawa T, Nishio A (1987) Mg^{2+}–Ca^{2+} interaction in contractility of vascular smooth muscle: Mg^{2+} versus organic calcium channel blockers on myogenic tone and agonist-induced responsiveness of blood vessels. Can J Physiol Pharmacol 65(4):729–745. doi:10.1139/y87-120

12. Ivanovski O, Szumilak D, Nguyen-Khoa T, Ruellan N, Phan O, Salem S, Bruck H, Bahlmann FH et al (2012) Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol 35(1):31–39. doi:10.1159/000334742

13. Montes de Oca A, Guerrero F, Martinez-Moreno JM et al (2014) The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int 67(6):2288–2294. doi:10.1038/ki.2013.1557.000332.x

14. Kircelli F, Peter ME, Sevink Ok E, Celenk FG, Yilmaz M, Steppan S, Asci G, Ok E, Passlick-Deetjen J (2012) Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner. Nephrol Dial Transplant 27(2):514–521. doi:10.1093/ndt/gfr321

15. Louvet L, Büchel J, Steppan S, Passlick-Deetjen J, Massy ZA (2013) Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. Nephrol Dial Transplant 28(4):869–878. doi:10.1093/ndt/gfs520

16. Montes de Oca A, Guerrero F, Martinez-Moreno JM et al (2012) Magnesium inhibits Wnt/β-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells. PLoS ONE 9(2):e89525. doi:10.1371/journal.pone.0089525

17. Fischer DC, Behetes GJ, Hakenberg OW, Voigt M, Vervaet BA, Robijn S, Kundt G, Schareck W, D’Haese PC, Haffner D (2012) Arterial microcalcification in atherosclerotic patients with and without chronic kidney disease: a comparative high-resolution scanning X-ray diffraction analysis. Calcif Tissue Int 90(6):465–472. doi:10.1007/s00223-012-9594-5

18. Van Laecke S, Marechal C, Verbeke F, Peeters P, Van Biesen W, Devuyst O, Jadoul M, Vanholder R (2011) The relation between hypomagnesaemia and vascular stiffness in renal transplant recipients. Nephrol Dial Transplant 26(7):2362–2369. doi:10.1093/ndt/gfr321

19. Kanbay M, Yilmaz MI, Apetrii M et al (2012) Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol 36(3):228–237. doi:10.1159/000341868

20. Mortazavi M, Moeinzedeh F, Saadatnia M, Shahidi S, McGee JC, Minagar A (2013) Effect of magnesium supplementation on carotid intima-media thickness and flow-mediated dilation among hemodialysis patients: a double-blind, randomized, placebo-controlled trial. Eur Neurol 69(5):309–316. doi:10.1159/000346427

21. Turgut F, Kanbay M, Metin M, Uz E, Akcay A, Covic A (2008) Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol 40(4):1075–1082. doi:10.1007/s11255-008-9410-3

22. Qu X, Jin F, Hao Y, Li H, Tang T, Wang H, Yan W, Dai K (2013) Magnesium and the risk of cardiovascular events: a meta-analysis of prospective cohort studies. PLoS ONE 8(3):e57720. doi:10.1371/journal.pone.0089525

23. Guasch-Ferres M, Bulló M, Estruch R et al (2014) Dietary magnesium intake is inversely associated with mortality in adults at high cardiovascular disease risk. J Nutr 144(5):59–60. doi:10.3945/jn.113.183012

24. Fragoso A, Silva AP, Gundlach K, Janine Büchel J, Leão Neves P (2014) Magnesium and FGF-23 are independent predictors of pulse pressure in pre-dialysis diabetic chronic kidney disease patients. Clin Kidney J 7(2):161–166. doi:10.1093/ckj/sfu003

25. Silva AP, Fragozo A, Silva C, Tavares N, Santos N, Martins H, Gundlach K, Büchel J, Camacho A, Faisca M, Jesus Varela I, Neves P (2014) Magnesium and mortality in patients with diabetes and early chronic kidney disease. J Diabetes Metab 5:347. doi:10.4172/2155-6156.1000347

26. Shechter M (2003) Does magnesium have a role in the treatment of patients with coronary artery disease? Am J Cardiovasc Drugs 3(4):231–239. doi:10.2165/00129784-200303040-00001

27. Matsuoka H, Kajita Y, Miwa M (2013) Magnesium deficiency increases serum fibroblast growth factor-23 levels in rats. Magnes Res 26(1):18–23. doi:10.1093/mrhr/20321

28. Covic A, Passlick-Deetjen J, Kroczak M, Büschges-Seraphin B, Gheu A, Ponce P, Marzell B, de Francisco AL (2015) A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant 29(9):2383–2392. doi:10.1093/ndt/gft203

29. Iguchi A, Watanabe Y, Iino N, Kazama JJ, Iesato H, Narita I (2014) Serum magnesium concentration is inversely associated with fibroblast growth factor 23 in haemodialysis patients. Nephrologie. 10.1111/nep.12287

30. Brown EM (1991) Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers. Physiol Rev 71:371–411

31. Kumar R, Thompson JR (2011) The regulation of parathyroid hormone secretion and synthesis. J Am Soc Nephrol 22(2):216–224. doi:10.1681/ASN.2010060186

32. Quinn SJ, Thomesen AR, Egbuna O, Fang J, Baxi K, Goltzman D, Pollak M, Brown EM (2013) CaSR-mediated interactions between calcium and magnesium homeostasis in mice. Am J Physiol Endocrinol Metab 304(7):E724–E733. doi:10.1152/ajpendo.00557.2012

33. de Francisco AL, Leidig M, Covic AC, Ketelers M, Benedyk-Lorens E, Mircescu GM, Scholz C, Ponce P, Passlick-Deetjen J (2010) Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CAL-MAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 25(11):3707–3717. doi:10.1093/ndt/gfq292

34. Rodríguez-Ortiz ME, Canalejo A, Herencia C et al (2014) Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration. Nephrol Dial Transplant 29(2):282–289. doi:10.1093/ndt/gft400

35. Holick MF (2006) Resurrection of vitamin D deficiency and other vitamin D disorders. J Clin Endocrinol Metab 91(5):1473–1486. doi:10.1210/jc.2005-0557.2012

36. Schöttker B, Ball D, Gellert C, Brenner H (2013) Serum 25-hydroxyvitamin D levels and overall mortality. A systematic review and meta-analysis of prospective cohort studies. Ageing Res Rev 12(2):708–718. doi:10.1016/j.arr.2012.02.004

37. Risco F, Traba ML (1992) Influence of magnesium on the in vitro synthesis of 24,25-dihydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitanm D3. Magnes Res 5(5):1–10

38. Rude RK, Adams JS, Ryan E, Endres DB, Niimi H, Horst RL, Haddad JG Jr, Singer FR (1985) Low serum concentrations of 1,25-dihydroxyvitamin D in human magnesium deficiency. J Clin Endocrinol Metab 60(5):933–940. doi:10.1210/jcem-61-5-933

39. Schöttker B, Ball D, Gellert C, Brenner H (2013) Serum 25-hydroxyvitamin D levels and overall mortality. A systematic review and meta-analysis of prospective cohort studies. Ageing Res Rev 12(2):708–718. doi:10.1016/j.arr.2012.02.004

40. Risco F, Traba ML (1994) Possible involvement of a magnesium dependent mitochondrial alkaline phosphate in the regulation of the 25-hydroxyvitamin D3-1 alpha-and 25-hydroxyvitamin D3-24R-hydroxylases in LLC-PK1 cells. Magnes Res 7(3–4):169–178
41. Rösler A, Rabinowitz D (1973) Magnesium-induced reversal of vitamin-D resistance in hypoparathyroidism. Lancet 1(7807):803–804. doi:10.1016/S0140-6736(73)90602-8
42. Deng X, Song Y, Manson JE, Signorelli LB, Zhang SM, Shrubsole MJ, Ness RM, Seidner DL, Dai Q (2013) Magnesium, vitamin D status and mortality: results from US National Health and Nutrition Examination Survey (NHANES) 2001 to 2006 and NHANES III. BMC Med 11:187. doi:10.1186/1741-7015-11-187
43. Cunningham J, Rodriguez M, Messa P (2012) Magnesium in chronic kidney disease stages 3 and 4 and in dialysis patients. Clin Kidney J 5(Suppl 1):139–151. doi:10.1093/ndtplus/sfr166
44. Rude RK, Singer FR, Gruber HE (2009) Skeletal and hormonal effects of magnesium deficiency. J Am Coll Nutr 28(2):131–141
45. Witteman JC, Willett WC, Stampfer MJ, Colditz GA, Sacks FM, Speizer FE, Rosner B, Hennekens CH (1989) A prospective study of nutritional factors and hypertension among US women. Circulation 80(5):1320–1327. doi:10.1161/01.CIR.80.5.1320
46. Ascherio A, Rimm EB, Giovannucci EL, Colditz GA, Rosner B, Manson J, Witteman J, Stampfer MJ (1996) Prospective study of nutritional factors, blood pressure, and hypertension among US women. Hypertension 27(5):1065–1072. doi:10.1161/01.HYP.27.5.1065
47. Song Y, Sesso HD, Manson JE, Cook NR, Buring JE, Liu S (2006) Dietary magnesium intake and risk of incident hypertension among middle-aged and older US women in a 10-year follow-up study. Am J Cardiol 98(12):1616–1621. doi:10.1016/j.amjcard.2006.07.040
48. Elwood PC, Fehily AM, Ising H, Pickering J, Kamel F (1999) Magnesium intake and risk of cardiovascular disease among women. Am J Cardiol 98(12):1616–1621. doi:10.1016/j.amjcard.2006.07.040
49. Dong JY, Xun P, He K, Qin LQ (2011) Magnesium intake and risk of type 2 diabetes: meta-analysis of prospective cohort studies. Diabetes Care 34(9):2116–2122. doi:10.2337/dc11-0518
50. Ascherio A, Rimm EB, Pham PM, Pham PM, Pham PA, Pham SV, Miller JM, Yanagawa N, Pham PT (2005) Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. Clin Nephrol 63(6):429–436
51. Dickinson HO, Nicolson DJ, Campbell F, Cook JV, Beyer FR, Del Gobbo LC, Song Y, Poirier P, Dewailly E, Elin RJ, Egeland BM, Escobedo LG, Caspersen CJ (1997) Risk factors for sudden coronary death in the United States. Epidemiology 8(2):175–180
52. Rodriguez-Morán M, Guerrero-Romero F (2003) Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care 26(4):1147–1152. doi:10.2337/diacare.26.4.1147
53. Huang JH, Lu YF, Cheng FC, Lee JN, Tsai LC (2012) Correlation of magnesium intake with metabolic parameters, depression and physical activity in elderly type 2 diabetes patients: a cross-sectional study. Nutr J 11:41. doi:10.1186/1475-2891-11-41
54. Al-Delaimy WK, Rimm EB, Willett WC, Stampfer MJ, Hu FB (2004) Magnesium intake and risk of coronary heart disease among men. J Am Coll Nutr 23(1):63–70
55. Liao F, Folsom AR, Brancati FL (1998) Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am J Cardiol 81(3):480–489. doi:10.1016/S0002-9343(97)00722-4
56. Ford ES (1999) Serum magnesium and ischaemic heart disease: findings from a national sample of US adults. Int J Epidemiol 28(4):645–651. doi:10.1093/ije/28.4.645
57. Abbott RD, Ando F, Masaki KH, Wang KH, Rodriguez BL, Petrovitch H, Yano K, Curb JD (2003) Dietary magnesium intake and the future risk of coronary heart disease (the Honolulu Heart Program). Am J Cardiol 92(6):665–669. doi:10.1016/S0002-9149(03)00819-1
58. Song Y, Hsu YH, Niu T, Manson JE, Buring JE, Liu S (2009) Common genetic variants of the ion channel transient receptor potential melastatin 6 and 7 (TRPM6 and TRPM7), magnesium intake, and risk of type 2 diabetes in women. BMC Med Genet 10:4. doi:10.1186/1471-2350-10-4
59. Nair AV, Hocher B, Verkaart S et al (2012) Loss of insulin-induced activation of TRPM6 magnesium channels results in impaired glucose tolerance during pregnancy. Proc Natl Acad Sci USA 109(28):11324–11329. doi:10.1073/pnas.1113811109
60. Prabodh S, Prakash DS, Sudhakar G, Chowdary NV, Devasai Y, Shekhar R (2011) Status of copper and magnesium levels in diabetic nephropathy cases: a case–control study from South India. Biol Trace Elem Res 142(1):29–35. doi:10.1007/s12111-010-8750-x
61. Ro¨ sler A, Rabinowitz D (1973) Magnesium-induced reversal of vitamin-D resistance in hypoparathyroidism. Lancet 1(7807):803–804. doi:10.1016/S0140-6736(73)90602-8
62. Dickson HO, Nicolson DJ, Campbell F, Cook JV, Beyer FR, Ford GA, Mason J (2006) Magnesium supplementation for the management of primary hypertension in adults (Review). Cochrane Database Syst Rev 3:1–55. doi:10.1002/14651858.CD004639.pub2
63. Dong JY, Xun P, He K, Qin LQ (2011) Magnesium intake and risk of type 2 diabetes: meta-analysis of prospective cohort studies. Diabetes Care 34(9):2116–2122. doi:10.2337/dc11-0518
64. Ascherio A, Rimm EB, Giovannucci EL, Colditz GA, Rosner B, Manson J, Witteman J, Stampfer MJ (1996) Prospective study of nutritional factors, blood pressure, and hypertension among US women. Hypertension 27(5):1065–1072. doi:10.1161/01.HYP.27.5.1065
65. Song Y, Sesso HD, Manson JE, Cook NR, Buring JE, Liu S (2006) Dietary magnesium intake and risk of cardiovascular disease among women. Am J Cardiol 98(6):1135–1141. doi:10.1016/j.amjcard.2005.06.045
66. Al-Delaimy WK, Rimm EB, Willett WC, Stampfer MJ, Hu FB (2004) Magnesium intake and risk of coronary heart disease among men. J Am Coll Nutr 23(1):63–70
67. Liao F, Folsom AR, Brancati FL (1998) Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 136(3):480–489. doi:10.1016/S0002-9713(97)00722-4
68. Ford ES (1999) Serum magnesium and ischaemic heart disease: findings from a national sample of US adults. Int J Epidemiol 28(4):645–651. doi:10.1093/ije/28.4.645
69. Xing JH, Soffer EE (2001) Adverse effects of laxatives. Dis Colon Rectum 44(8):1201–1209
70. Joosten MM, Gansevoort RT, Mukamal KJ, Kootstra-Ros JE, Feskens EJ, Geleijnse JM, Navis G, Bakker SJ, Feskens EJ, Geleijnse JM, Navis G, Bakker SJ, PREVEND Study Group (2013) Urinary magnesium excretion and risk of hypertension: the prevention of renal and vascular end-stage disease study. Hypertension 61(6):1161–1167. doi:10.1161/HYPERTENSIONAHA.113.01333
71. Joosten MM, Gansevoort RT, Mukamal KJ, van der Harst P, Geleijnse JM, Feskens EJ, Navis G, Bakker SJ, PREVEND Study Group (2013) Urinary and plasma magnesium and risk of ischemic heart disease. Am J Clin Nutr 97(6):1299–1306. doi:10.3945/ajcn.112.054114
75. Bonner A, Wellard S, Caltabiano M (2008) Levels of fatigue in people with ESRD living in far North Queensland. Clin Nurs 17(1):90–98. doi:10.1111/j.1365-2702.2007.02042.x

76. Horigan A, Rocchiccioli J, Trimm D (2012) Dialysis and fatigue: implications for nurses—a case study analysis. Medsurg Nurs 21(3):158–163

77. Hedayati SS, Yalamanchili V, Finkelstein FO (2012) A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease. Kidney Int 81(3):247–255. doi:10.1038/ki.2011.358

78. Li X, Frye MA, Shelton RC (2012) Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology 37(1):77–101. doi:10.1038/npp.2011.198

79. Murck H (2013) Ketamine, magnesium and major depression—from pharmacology to pathophysiology and back. J Psychiatr Res 47(7):955–965. doi:10.1016/j.jpsychires.2013.02.015

80. Szewczyk B, Poleszak E, Sowa-Kucma M et al (2008) Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action. Pharmacol Rep 60(5):588–589

81. Socała K, Nieoczym D, Poleszak E, Właż P (2012) Influence of the phosphodiesterase type 5 inhibitor, sildenafil, on antidepressant-like activity of magnesium in the forced swim test in mice. Pharmacol Rep 64(1):205–211

82. Poleszak E, Szewczyk B, Kędzierska E, Właż P, Pilec A, Nowak G (2004) Antidepressant- and anxiolytic-like activity of magnesium in mice. Pharmacol Biochem Behav 78(1):7–12. doi:10.1016/j.pbb.2004.01.006

83. Cox IM, Campbell MJ, Dowson D (1991) Red blood cell magnesium and chronic fatigue syndrome. Lancet 337(8744):757–760. doi:10.1016/0140-6736(91)91371-Z

84. Barragán-Rodríguez L, Rodríguez-Morán M, Guerrero-Romero F (2008) Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: a randomized, equivalent trial. Magnes Res 21(4):218–223. doi:10.1684/mrh.2008.0149

85. Maduell F, Pérez N, Arias M et al (2012) Calcium acetate and magnesium carbonate association: a good alternative of calcium-based phosphate binders. Nephrol Dial Transplant 27(2):506. doi:10.1093/ndt/gfs245

86. De Schutter TM, Behets GJ, Gery H, Peter ME, Steppan S, Gundlach K, Passlick-Deetjen J, D’Haese PC, Neven E (2013) Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia. Kidney Int 83(6):1109–1117. doi:10.1038/ki.2013.34